

CURRICULUM VITAE



Privatdozent (A/Prof) Dr. Behrooz Hooshyar Yousefi, (PhD)

Nuclear Medicine Department
Philipps University Marburg
Baldingerstraße, D-35043 Marburg

Phone: +49 6421/58-65806; +4915785219441
b.h.yousefi@uni-marburg.de

Position

Head of Radiopharmacy section and Deputy Head of the Small Animal Molecular Imaging Core Facility (ZTI), Radiation safety officer, Project manager for genetic engineering work of S1 and S2

Date of Birth

22.08.1965

Gender

Male

Children

2

Current Positions

2019 – date

Head of radiopharmacy section, University staff and group leader
Radiation safety officer, School of medicine of Philipps University Marburg

Academic Career

2015 – 2019

Head Neuroradiopharmacy and research group leader at Nuclear Med. Dept., Technical University Munich (TUM)

2018

Privatdozent (A/Prof.) Experimental Nuclear Medicine- Radiopharmacy at School of Medicine, TUM

2005 – 2015

PI at Nuclear Medicine Department and Pharmaceutical Radiochemistry Chair, TUM, Munich, Germany.

2005

Senior Scientist at Chemistry and Biochemistry Institute, TU-Darmstadt, Darmstadt, Germany

2001 – 2002

Assistant Prof. of Drug Synthesis and Medicinal Chemistry, Tabriz University of Medical Sciences, Tabriz, Iran

Education and Training

2011 – 2017

Habilitation, "Experimental Nuclear Medicine" Radiopharmacy at Technische Universität München, Munich, Germany

2004 – 2/2005

Postdoctoral research, Vienna University of Technology, Vienna, Austria

2002 – 2003

Postdoctoral fellow, Karl-Franzens University of Graz, Graz, Austria

1995 – 2000

Doctoral student of Organic Chemistry at Chemistry Faculty, Tabriz University

1998 – 1999

PhD research visiting, Organic Chemistry Institute, JL-University Gießen.

1991 – 1994

M.Sc. student of Organic Chemistry at Chemistry department of Tehran University

1984 - 1988

B.Sc. student of Chemistry at Chemistry department of Tabriz University

Other

- Military service 27 months 1989-1991 and parent sabbaticals for 2 children.

- Member of European Association of Nuclear Medicine, German association of Nuclear Medicine (DGN) and Working Group Radiochemistry-Radiopharmacy of the German Society of Nuclear Medicine.

- Editorial board and guest editor for several journals such as Frontier in Aging Neuroscience, Frontiers in Neuroscience, Journal Medicinal Chemistry and Current Chemistry Letters. Extensive referee assignments in radiopharmacy, oncology- and neuro-imaging such as in J Med Chem, Eur J Nucl Med Mol Imaging, ACS, Bioorg Med Chem Lett, Bioconjug Chem, Molecular Neurodegeneration, Nucl Med Biol, Cancers, Diagnostics, pharmaceuticals, biomedicines and Molecules.

- Several personal invitations to speak at international conferences and symposiums such as:

-International congress of Chemistry, Keynote lecturer Tabriz Jul. 2022

-Peking University International Brain Research Conference Keynote lecturer "PET radiopharmaceuticals for AD and PD diagnosis, the current and future landscape" Oct. 2019, Beijing, China.

-University Clinic Cologne symposium, Nuclear medicine department, "Pitfalls and recent advances in developing a PET tracer for α -synuclein aggregates", 19th Feb. 2018. Cologne, Germany

-The 17th Eibsee DFG-Synergy symposium Cellular Mechanisms Of Neurodegeneration Oct 25-27, "PET radiotracer development for non-invasive diagnosis of neurodegenerative diseases" 2017, Eibsee, Germany.

-Tabriz University, organized a Workshop at Chemistry faculty, Nov. 18th 2015, "Radiotracers for imaging neurodegenerative disorders".

-2nd Iranian Congress on Human Brain Mapping" to be held in, Tehran, Iran from November 14-16th 2015, „Novel radiotracers for imaging prote(in)opathies in neurodegenerative disorders “

-Evotec neuroscience symposium, May 5th 2015, Hamburg. "Radiopharmaceutical and Experimental Nuclear Medicine Research for Imaging in Neurodegenerative Disorders"

" Development of New Tracers for Imaging of Neurodegenerative Disorders" Neurosciences Research Center (NSRC), Imam REZA Medical Center, Tabriz University of Medical sciences, Nov. 22, 2015. "Novel Radiopharmaceuticals for neuroimaging"

-DZNE symposium, München, Sep.12, 2015. "Neuroimaging of Proteopathies"

-Marburger Parkinson-Symposium, Studienzentrale Kompetenznetz Parkinson, March 06-07, 2014

Awards & Honors

2023

Thomas Behr Poster Award of the MGN 2023

2016

The best scientific publication prize Nuclear Medicine Department at TUM.

2002-2005

Austrian Academic Exchange postdoctoral award at Graz University and Technical University Vienna (Medicinal Chemistry).

1998-1999

Iranian Ministry of Culture and Higher Education award one year, visiting scientist at JLU-Giessen University, Germany

Courses and certificates

- **Radiation protection courses** for the expert group S4.2 modules GH and OH
- **Technical qualification in radiation protection and radiation protection officer**
- **Project manager of genetic engineering work** / Representative for biological safety according to §§15 and 17 of the Genetic Engineering Safety Ordinance
- **GMP-training courses** for pharmaceutical quality assurance and drug safety, Qualification / Validation in Analytical Procedures, GMP-Basis training on pharmaceutical quality control provided by Analytic-Service - Dr. T. Trantow, Schöneiche, Berlin
- **Advance Certificate in Preclinical Imaging**, DGN, Bregenz
- **PMOD Basic Application and Small Animal Image Processing** Courses provided by PMOD Technologies Ltd, Zurich, Swiss
- **Lecturer Training Workshop** of the Faculty of Medicine/Seminar Center Frauenchiemsee, March 2016, Klinikum r.d. Isar, TUM.
- **ProLehre** - The university didactics Munich center for Technology in Society, Giving Academic Talks in English, April 2016.

Clinically oriented responsibilities

- | | |
|-------------|--|
| 2006 – 2011 | Establishment of new automated [¹¹ C]PiB synthesis and being Qualified Person for Amyloid PET of Alzheimer patients, at TUM. Several [¹¹ C]chemistry for variety of research projects. |
| 2012 – 2018 | Establishment of new Amyloid PET tracer, first-in-human and pilot studies of self-developed amyloid PET tracer, [¹⁸ F]FIBT including automation and CMC |
| 2015 – 2019 | Establishment of new PET tracers [¹⁸ F]T807 for tau imaging, [¹⁸ F]LMI1195 for cardiac neural imaging, [¹⁸ F]DOPA, the first self-developed α-synuclein PET-[¹⁸ F]FS3-1 including automation and CMC. |
| 2019– | Establishment of new targeted alpha-therapy (TAT) ²²⁵ Ac-prostate specific membrane antigen treatment benefit in metastatic castrate-resistant prostate cancer patients, refractory to standard therapies, is another game-changing piece in the short history of TAT clinical application with radiotracer [²²⁵ Ac]PSMA-617. |

Scientific focus

Development of specific molecular imaging and radiopharmaceuticals for non-invasive imaging and therapy monitoring with PET and SPECT, new strategies for radiolabeling and production of radiopharmaceuticals majorly for neurological questions: new ligands for neuropathological protein aggregates to enable imaging of severe neurodegenerative diseases. Along this path, pharmaceutical radiochemistry and multimodal small animal imaging are important fields of activity for me. "Molecular imaging. Main radionuclides used in clinical and research setups: ¹¹C, ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I, ¹³¹I, ⁶⁸Ga, ^{99m}Tc, ¹⁷⁷Lu and ²²⁵Ac.

Previous Funding

2019-2022	DAAD Research Grants – a Doctoral scholarship for my PhD candidate "Development and evaluation of radiotracers for α -synuclein aggregates imaging" (ST32-57381412); [~100.000 €]
2015-2018	EU (FP7; MINDVIEW) Development of neurotransmitters PET to better diagnose and consequently to better treat schizophrenia. Role: lead scientist (TUM); [~390.000 €]
2012-2015 2011	DFG: Improved amyloid tracer for CAA, Role: Co-PI. (TUM) [~380.000 €] Bayer-Schering G4T, tau tracer development. Role: Co-PI [50.000 €]
2009-2011	BMBF: MINDE Role: Co-Investigator and PI (TUM) with Prof. Schmidt TU-Darmstadt [~380.000 €]
2005-2008	DFG: Tracers for selective β -Amyloid PET, Role: chief scientist (TUM) [~400.000 €]

Recent projects

2020-2023	Flexi-Funds project „Lung-brain axis in health and disease“, project number 2019_2_1_3 by Forschungscampus Mittelhessen (FCMH) with the lead by Prof. Christiane Herden and Christoph Rummel. Role: subproject PI of radiopharmacy and in vivo imaging. [30.000€]
2021-2023	Development of a selective α -synuclein PET tracer for early diagnosis of α -synucleinopathies– Translational PET imaging research Parkinsonfonds-Deutschland Grant, Role: PI [290.000 €]

Submitted

2023-Pending	BMBF: DAT pilot Modul 1 - Innovationssprints, „Charakterisierung und erstmalige Anwendung von innovativen zur Bildgebung von α -Synuclein-Fibrillen (aSYN) bei Patienten mit Parkinson-Krankheit (PD) und Demenz mit Lewy-Körperchen (DLB) mittels Positronen-Emissions-Tomographie (PET)“ Role: PI [300.000 €]
--------------	--

Teaching Experience

Lectures in Iran

1995-2002	Organic Chemistry, Molecular Spectroscopy theory and experimental and General Chemistry theory and experimental, Medicinal chemistry - Drug synthesis part, Tabriz University & Tabriz Med. Sci. University.
2003-2005	Microwave assisted Organic/Medicinal chemistry workshop, Uni Graz (2003), Uni Yazd (2004) and Tabriz Med. Sci. University 2005.
July 2022	Radiopharmacy workshop Shahid Madani Univ. Tabriz.
August 2023	One-week Radiopharmacy workshop Department of Med. Phys., Isfahan University, Isfahan.

Lectures in Germany

2007-2018

Pharmaceutical radiochemistry I and II at TUM:

- Alzheimer's disease diagnostics and tracer development
- Microwave assisted radiochemistry

Special aspects of radiopharmacy:

- Radiopharmaceuticals for infection imaging
- Electrospray and tandem MS in PRC

3rd Radiopharmacy Seminar:

- Cherenkov luminescence tomography for radiopharmaceutical imaging

2007-2023

Student Practicum: Autoradiography and binding assay experiments

Several Research Internship

Several Bachelor theses

PhD, MD and Master thesis >10

Currently Ms. Shamim Bagheri (Dr. rer. med. student), Ms. Azimeh Hojjat (Dr. rer. nat. candidate), Mr. Ali Ebrahifard (Dr. rer. nat. student) and Mr. Qi Wang (Dr. med candidate).

2011-2019

PhD course: Hands-on preclinical imaging:

- Biomarkers for Alzheimer diagnostics, example of tracer development
- Translational research as "bench-to-bedside", from laboratory experiments to preclinical studies to point-of-care patient investigations.

2018-2023

PhD and MD seminar course "Pharmacokinetics and Metabolism in Neuro-radiopharmaceutical Design"

Language skills

German (B2, Excellent)

English (very good written and spoken)

Persian and Azari mother languages.

Selected publications

Google Scholar (<https://scholar.google.de/citations?user=8RhlyokAAAAJ&hl=en>)

h-index 24, citations 2205, i10-index 39[IF= impact factor]

B Uzuegbunam, J Li, W Paslawski, W Weber, P Svenningsson, H Ågren, **BH Yousefi** In silico and in vitro study towards the rational design of 4,4'-disarylbi-thiazoles as a selective α -synucleinopathy biomarker Int. J. Mol. Sci. 2023, 24(22), 16445; <https://doi.org/10.3390/ijms242216445>

Abdallah M Ayoub, Muhammed S Atya, Ahmed M Abdelsalam, Jan Schulze, Muhammad U Amin, Konrad Engelhardt, Matthias Wojcik, Damiano Librizzi, **Behrooz H Yousefi**, Usman Nasrullah, Josef Pfeilschifter, Udo Bakowsky, Eduard Preis Photoactive Parietin-loaded nanocarriers as an efficient therapeutic platform against triple-negative breast cancer International Journal of Pharmaceutics, Volume 643, 2023, 123217, ISSN 0378-5173, <https://doi.org/10.1016/j.ijpharm.2023.123217>. [IF 3.1]

Jan Schulze, Damiano Librizzi, Lena Bender, Jarmila Jedelská, **Behrooz H Yousefi**, Jens Schaefer, Eduard Preis, Markus Luster, Andreas H Mahnken, Udo Bakowsky How to Xenograft Cancer Cells on the Chorioallantoic Membrane of a Fertilized Hen's Egg and Its Visualization by PET/CT and MRI ACS Applied Bio Materials 2023 6 (6), 2435-2445. DOI: 10.1021/acsabm.3c00237 [IF 4.7]

Damiano Librizzi, Friederike Eilsberger, Stefan Ottenthaler, Ali Ebrahimifard, Markus Luster, **Behrooz H Yousefi** Diagnostic Impact of Dual-Time PET/CT with ^{68}Ga -PSMA in Prostate Cancer and ^{68}Ga -DOTATOC in Neuroendocrine Tumors Biomedicines 2023, 11(4), 1052; <https://doi.org/10.3390/biomedicines11041052> [IF 4.7]

Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, Ågren H, **Yousefi BH** Towards Novel [^{18}F]Fluorine-labeled Radiotracers for the Imaging of α -Synuclein Fibrils. Front. Aging Neurosci., 29 April 2022 | <https://doi.org/10.3389/fnagi.2022.830704> [IF 4.8]

- Librizzi D, Cabanel N, Zavorotnyy M, Riehl E, Kircher T, Luster M, **Yousefi BH** Clinical Relevance of [¹⁸F]Florbetaben and [¹⁸F]-FDG PET/CT Imaging on the Management of Patients with Dementia. *Molecules* 2021, 26, 1282. <https://doi.org/10.3390/> [IF 4.927]
- Kessler L, Schlitter AM, Kroenke M, von Werder A, Tauber R, Maurer T, Robinson SP, Orlandi C, Herz M, **Yousefi BH**, Nekolla SG, Schwaiger M, Eiber M, Rischpler C. First experience using F-18-flubrobenguane PET imaging in patients with the suspicion of pheochromocytoma or paraganglioma *J Nucl Med* 2020 Aug 28; jnumed.120.248021. doi: 10.2967/jnumed.120.248021 [IF 10.057]
- Niu Z, Sarkar R, Aichler M, Wester HJ, **Yousefi BH***, Reif B* Mapping the Binding Interface of PET Tracer Molecules and Alzheimer Disease A β Fibrils by Using MAS Solid-State NMR Spectroscopy *Chembiochem*. 2020 Apr 15. doi: 10.1002/cbic.202000143 [IF 3.164]
- Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A and **Yousefi BH** ¹⁸F-FIBT may expand PET for β -amyloid imaging in neurodegenerative diseases *Molecular Psychiatry* 2020, 25 (10), 2608-2619 [IF 15.992]
- Brendel M*, **Yousefi BH*** et al. A Comparison of ¹⁸F-T807 and ¹⁸F-THK5117 PET in a Mouse Model of Tau Pathology *Front Aging Neurosci*. 2018; 10: 174 [IF 3.633]
- Robu S, Schmidt A, Eiber M, Schottelius M, Günther T, **Yousefi BH**, Schwaiger M and Wester HJ Synthesis and preclinical evaluation of novel ¹⁸F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with ¹⁸F-DCFpyl and ¹⁸F-PSMA-1007 *EJNMMI Research* 2018 8:30, <https://doi.org/10.1186/s13550-018-0382-8>. [IF 3.00]
- Lee M, Minaskan N, Wiedemann T, Irmeler M, Beckers J, **Yousefi BH**, et al. Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo. *Endocr Relat Cancer*. 2017;24(1):1-15. DOI:10.1530/ERC-16-0324. [IF 5.331]
- Tahmasian M, Shao JM, Meng C, Grimmer T, Diehl-Schmid J, **Yousefi BH**, et al. Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study. *Journal of Nuclear Medicine* 2016;57(3):410-5. DOI:10.2967/jnumed.115.165464. [IF 6.646]
- Higuchi T*, **Yousefi BH***, Reder S, Beschorner M, Laitinen I, Yu M, et al. Myocardial Kinetics of a Novel [¹⁸F]-Labeled Sympathetic Nerve PET Tracer LMI1195 in the Isolated Perfused Rabbit Heart. *Jacc-Cardiovasc Imag*. 2015; 8(10):1229-31. [IF 7.815]
- Yousefi BH***, Manook A*, Grimmer T, Arzberger T, von Reutern B, Henriksen G, et al. Characterization and First Human Investigation of FIBT, a Novel Fluorinated A beta Plaque Neuroimaging PET Radioligand. *ACS Chemical Neuroscience*. 2015; 6(3):428-37. DOI: 10.1021/cn5001827. [IF 4,348]
- Yousefi BH**, von Reutern B, Scherübl D, Manook A, Schwaiger M, Grimmer T, Henriksen G, Förster S, Drzezga A and Wester HJ FIBT versus Florbetaben and PiB: a Preclinical Comparison Study with Amyloid-PET in Transgenic Mice, *EJNMMI Res*. 2015 5:20 DOI 10.1186/s13550-015-0090-6. [IF 1.761]
- Ortner M, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid J, Drzezga A, Förster S, Förstl H, Perneczky R, Sorg C, **Yousefi BH**, Grimmer T. Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer's Disease. *Biol Psychiatry*. 2014. pii: S0006-3223(14)00058-4. [IF 10.255]
- Klupp E, Grimmer T, Tahmasian M, Sorg C, Yakushev I, **Yousefi BH**, Alexander Drzezga, Stefan Förster Prefrontal hypometabolism in AD is related to longitudinal amyloid accumulation in remote brain regions. *Journal of Nuclear Medicine* 2015, DOI:10.2967/jnumed.114.149302. [IF 5.849]
- Klupp E, Förster S, Grimmer T, Tahmasian M, Yakushev I, Sorg C, **Yousefi BH**, Drzezga A In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions. *Brain connectivity* 2014, DOI: 10.1089/brain.2013.0212. [IF 5.24]
- Higuchi T, **Yousefi BH**, Kaiser F, Gaertner F, Rischpler C, Reder S, Yu M, Robinson S, Schwaiger M, and Nekolla S Assessment of the ¹⁸F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts, *J. Nucl. Med*. 2013, 54, 1142-1146. [IF 5.563]

von Reutern B, Grunecker B, **Yousefi BH**, Henriksen G, Czisch M and Drzezga A Voxel-based analysis of amyloid-burden measured with [¹¹C]PiB PET in a double transgenic mouse model of Alzheimer's disease, *Mol Imaging Biol* 2013,15, 576-584. [IF 2.869]

Manook A, **Yousefi BH**, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, and Drzezga A Small-animal PET imaging of amyloid-beta plaques with [¹¹C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease, *PLoS One* 2012, 7, e31310. 3,730

Grimmer T., Faust M., Auer F., Alexopoulos P., Foerstl H., Henriksen G., Perneczky R., Sorg C., **Yousefi B. H.**, Drzezga A., and Kurz A. White matter hyperintensities predict amyloid increase in Alzheimer's disease, *Neurobiol. Aging* 2012, 33, 2766-2773. [IF 6.166]

Foerster S., Grimmer T., Miederer I., Henriksen G., **Yousefi B. H.**, Graner P., Wester H.-J., Foerstl H., Kurz A., Dickerson B. C., Bartenstein P., and Drzezga A. Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay, *Biol. Psychiatry* 2012, 71, 792-797. [IF 9.247]

Yousefi BH, Manook A, von Reutern B, Schwaiger M, Drzezga A, Wester HJ, Henriksen G. Development of an improved radioiodinated 2-phenylimidazo[1,2-a]pyridine for non-invasive imaging of amyloid plaques. *RSC Med. Chem. Commun.* 2012, 3, 775-779. [IF 2.722]

Yousefi BH, Drzezga A, von Reutern B, Manook A, Schwaiger M, Wester HJ, Henriksen G A Novel ¹⁸F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β -Amyloid Plaques *ACS Med. Chem. Lett.* 2011, 2, 673–677. [IF 3.355]

Yousefi BH, Manook A, Drzezga A, von Reutern B, Schwaiger M, Wester HJ, Henriksen G, Synthesis and Evaluation of ¹¹C-Labeled Imidazo[2,1-b]benzothiazoles (IBTs) as PET Tracers for Imaging β -Amyloid Plaques in Alzheimer's Disease. *J. Med. Chem.* 2011, 54 (4), 949-956. [IF 5.248]

Grimmer T, Tholen S, **Yousefi BH**, Alexopoulos P, Foerschler A, Foerstl H, Henriksen G, Klunk WE, Mathis CA, Perneczky R, Sorg C, Kurz A, and Drzezga A Progression of cerebral amyloid load is associated with the apolipoprotein E ϵ 4 genotype in Alzheimer's disease, *Biol. Psychiatry* 2010, 68, 879-884. [IF 8.674]

Bahrami K, Khodaei MM, **Yousefi BH**, and Arabi MS TMSCl-promoted selective oxidation of sulfides to sulfoxides with hydrogen peroxide, *Tetrahedron Lett.* 2010, 51, 6939-6941. [IF 2.618]

Marton J, Schoultz BW, Hjernevik T, Drzezga A, **Yousefi BH**, Wester HJ, et al. Synthesis and evaluation of a full-agonist orvinol for PET-imaging of opioid receptors: [¹¹C]PEO. *J Med Chem* 2009;52(18):5586-9. [IF 4.802]

Henriksen G, **Yousefi BH**, Drzezga A, Wester HJ, Development and evaluation of compounds for imaging of β -amyloid plaque by means of positron emission tomography. *Eur J Nucl Med Mol Imaging* 2008, 35 Suppl 1, S75-81. [IF 4.532]

Henriksen G, Hauser AI, Westwell AD, **Yousefi BH**, Schwaiger M, Drzezga A, Wester HJ Metabolically stabilized benzothiazoles for imaging of amyloid plaques. *J Med Chem.* 2007, 50 (6), 1087-9. [IF 4.895]

Inventor of several innovative patents for radiolabelling and novel radiotracers:

-WO 2015004029 A1, Jan 15, 2015 ¹⁸F-labeling of aromatic and heteroaromatic molecules containing unprotected carboxylic acid groups using cryptate mediated no-carrier-added nucleophilic fluorination Yousefi BH, Bollinger M, Kessler H, Wester H-J.

-WO2010092111A2, EP2218464 A1, PCT/EP2010/051704, DE112010000820 T5, 2010, Compounds for non-invasive measurement of aggregates of amyloid peptides; Henriksen G, Yousefi BH, Wester H-J.

-EP1944281A1. 2008. Preparation of ¹⁸F-labeled aniline derivatives for use as diagnostic agents in non-invasive imaging; Henriksen G, Hooshyar Yousefi B, Wester H-J.

EP20070100290, 01/09/2007, **¹⁸F-labeled compounds, method for the preparation and use thereof**; Henriksen, G., Yousefi, B. H., Wester H-J .

-Two Iranian national patents in process chemistry during my MSc research.

More recently **US10328163B2** "Compounds binding to neuropathological aggregates" which consist of selective radiotracers for imaging α -synucleinopathies is granted.

Book Chapters


-Kappe CO et al. Adventures in microwave-assisted organic synthesis: Contributions from the Kappe Laboratory 2000-2005. NATO Sci Ser, II. 2008;246 (New Methodologies and Techniques for a Sustainable Organic Chemistry):225-51.

-Yousefi BH, Wester HJ, 2015, "Development of ^{18}F -labeled compounds for imaging of A β plaques by means of PET", In: Fluorinated Pharmaceuticals: Advances in Medicinal Chemistry, Westwell AD (editor); ISBN: 978-1-910419-00-7 © 2015 Future Science Ltd

Summary of management, development and collaboration skills

Scientific collaboration with other research groups, in particular TUM, LMU, DZNE, Karolinska Institute, Uppsala University and Bern University on novel PET tracers towards selective α -synucleinopathy imaging. Experience in collaboration with industry.

Sincerely,



Behrooz Hooshyar Yousefi